Abstract
Plasma levels of clozapine and its major metabolites,N-desmethylclozapine and clozapine-N-oxide, were measured in 18 schizophrenic patients at different times (4, 6 and 24 weeks) during the course of treatment with multiple doses of the drug, by using high performance liquid chromatography (HPLC) with UV detection. Plasma levels of clozapine andN-desmethylclozapine were significantly higher in females than in males after 4 and 6 weeks, but not after 24 weeks, of treatment. No sex difference was found at any time with respect to plasma levels of clozapine-N-oxide.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ackenheil M (1989) Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 99:S36-S37
Bondesson U, Lindstrom LH (1988) Determination of clozapine and itsN-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology 95:472–475
Choc MG, Lehr RG, Hsuan F, Honigfeld G, Smith HT, Borison R, Volavka J (1987) Multiple dose pharmacokinetics of clozapine in patients. Pharm Res 4:402–405
Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, Zarifian E (1989) Substantial rose in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 27:272–275
Haring C, Meise V, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H (1989) Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 99:S38-S40
Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A (1990) Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 147:1471–1475
Hasegawa M, Gutierrez-Esteinon R, Way L, Meltzer HY (1993) Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 13:383–390
Lin SK, Chang WH, Chung MC, Lan YWF, Jann MW (1994) Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol 34:318–324
Perry PJ, Miller DD, Arnott SV, Cadoret RJ (1991) Clozapine and Norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231–235
Spina E, Martines E, Caputi AP, Cobaleda J, Pinas B, Carrillo JA, Benitez J (1991) Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 41:467–470
Spina E, Campo GM, Calandra S, Caputi AP, Carrillo JA, Benitez J (1992) Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients. Pharmacol Res 25:43–50
Volpicelli SA, Centorrino F, Puopolo PR, Kando J, Frankenburg FR, Baldessarini RJ, Flood JG (1993) Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography. Clin Chem 39:1656–1659
Weigmann H, Hiemke C (1992) Determination of clozapine and its major metabolites in human serum using automated solidphase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J Chromatogr 583:209–216
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fabrazzo, M., Esposito, G., Fusco, R. et al. Effect of treatment duration on plasma levels of clozapine andN-desmethylclozapine in men and women. Psychopharmacology 124, 197–200 (1996). https://doi.org/10.1007/BF02245621
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245621